We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Rapid POC Test Developed to Detect Influenza

By LabMedica International staff writers
Posted on 22 May 2017
Print article
Image: Scientists are developing a disposable, POC flu detector that yields visible results in about 35 minutes (Photo courtesy of the American Chemical Society).
Image: Scientists are developing a disposable, POC flu detector that yields visible results in about 35 minutes (Photo courtesy of the American Chemical Society).
Addressing the perennial threat of a major flu pandemic, researchers have developed fast, easy-to-use point-of-care (POC) diagnostic test for influenza that could head off rapid spread of the virus during an outbreak. Preliminary clinical testing of the prototype device were encouraging.

Existing rapid diagnostic tests can help with diagnoses but require multiple processing steps that still need to be performed with lab equipment in specialized facilities. Prof. Paul Yager, University of Washington, and colleagues set out to create a simpler, low-cost device that overcomes these difficulties. The researchers incorporated multiple steps of influenza detection – viral lysis, target protein capture, labeling, rinsing, and an enzyme-driven color change – into one device. A user swabs the inside of a patient’s nose, inserts the swab into the device, and twirls it for 10 seconds to release the virus. The device takes care of the rest. After about 35 minutes (total test time from device initiation to result), it produces a visual readout that can be seen with the naked eye and recorded with a smartphone camera. The materials and reagents for one of these single-use disposable devices cost less than USA 6.

The test is based on a sandwich immunoassay for influenza virus nucleoprotein and runs in a 2-dimensional paper network format. The device contains all reagents and required no dedicated instruments.

The researchers trained clinical staff at Seattle Children’s Hospital to use the prototype device to detect influenza A and B in those specimens. 25 patients were tested during a flu outbreak. Influenza A was detected, with accuracy of ∼70% based on in-house qRT-PCR influenza A as a gold-standard comparison. The ratio of valid to total completed device runs yielded a success rate of 92%, and the negative predictive value for both the influenza A and B assay was 81%. The ability to diagnose respiratory infections rapidly and close to the patient was well received by hospital staff, inspiring further optimization of device function.

The study, by Huang S et al, was published April 26, 2017, in the journal Analytical Chemistry.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: The QIAseq xHYB Mycobacterium tuberculosis Panel uses next-generation sequencing (Photo courtesy of 123RF)

New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance

Tuberculosis (TB), the leading cause of death from an infectious disease globally, is a contagious bacterial infection that primarily spreads through the coughing of patients with active pulmonary TB.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.